GLP1R and Alzheimer disease: On the contrary, the proportion of discontinuers was lower among incident treatments of more recently marketed ADs, such as GLP1-RA and fixed-dose combinations of metformin+SGLT2i and metformin + DPP4i (p-values < 0.05 for comparison with other AD groups) (Figure 5).